Page 3 - KIDNEY CANCER

Sunitinib versus cabozantinib, crizotinib or savolitinib in

metastatic papillary renal cell carcinoma (pRCC): Results from

the randomized phase II SWOG 1500 study

Sumanta K. Pal, Catherine Tangen, Ian Murchie Thompson Jr., Naomi B. Haas, Daniel J. George, Daniel Yick
2
1
5
3
4
6
9
8
7
Chin Heng, Brian M. Shuch, Mark N. Stein, Maria S. Tretiakova, Peter Humphrey, 10 Adebowale Adeniran, 10 Vivek
13
Narayan, 11 Georg A. Bjarnason, 12 Ulka N. Vaishampayan, 13 Ajjai Shivaram Alva, Tian Zhang, 14 Scott Wesley
Cole, 15 Melissa Plets, John Wright, 16 Primo N. Lara Jr. 17
2
1
Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA; SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA; Christus
2
4
3
5
Santa Rosa Medical Center Hospital, Houson, TX; Abramson Cancer Center, University of Pennsylvania (ECOG-ACRIN), Philadelphia, PA; Duke University Medical Center, Durham, NC; Department of
Oncology, Tom Baker Cancer Center, Calgary, AB; Institute of Urologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA; Columbia University Medical Center, New York, NY; 8
6
7
9
University of Washington, Seattle, WA; Yale University, New Haven, CT; 10 University of Pennsylvania, Philadelphia, PA; 11 Sunnybrook Odette Cancer Centre (CCTG), Toronto, ON; 12 University of Michigan,
Ann Arbor, MI; 13 Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC; 14 Oklahoma Cancer Specialists and Research Institute (NRG Oncology), Tulsa, OK; 15
National Cancer Institute, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD; 16 UC Davis Comprehensive Cancer Center, Sacramento, CA 17

Slides courtesy of Drs.Sumanta K. Pal and Stephanie Berg